Evidence map›Paper›PMID 34027224›Full record

ArticleContemporary clinical trials communications2021

Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research.

Colin Cernik, Elena Shergina, Jeffrey Thompson, Karen Blackwell, Kyle Stephens, Kim S Kimminau, Jo Wick, Matthew S Mayo, Byron Gajewski, Jianghua He and 1 more

Abstract read
In one paragraph

Article in Contemporary clinical trials communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Colin CernikDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Elena SherginaDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Jeffrey ThompsonDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Karen BlackwellHuman Research Protection Program, University of Kansas Medical Center, Kansas City, KS, USA.
Kyle StephensHuman Research Protection Program, University of Kansas Medical Center, Kansas City, KS, USA.
Kim S KimminauDepartment of Family and Community Medicine, University of Missouri , Columbia, MO, USA.
Jo WickDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Matthew S MayoDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Byron GajewskiDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Jianghua HeDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Dinesh Pal MudaranthakamDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial process of review and approval is known as the study start-up process (SSU). We evaluated the average time taken for studies to receive approvals. Using data from clinical trials conducted at the University of Kansas Medical Center, various times to reach the start of the study were calculated based on the dates of individual study. The results of this analysis showed that chart review studies and investigator-initiated trials had a shorter time to activation than other types of studies. Additionally, single-center studies had a shorter activation time than multi-center studies. The analysis also demonstrated that the overall processing time consistently had been reduced over time.

Indexed as

Clinical trial activationInstitutional review board review

Identifiers

PMID34027224
PMCPMC8121646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.